Real-World Outcomes in Diabetic Macular Edema for the 0.2 µg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK

References

• Sivaprasad S, Gupta B, Gulliford MC, et al. Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (drive uk). PLoS One. 2012;7(3):e32182–e82. doi:10.1371/journal.pone.0032182
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research N. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi:10.1056/NEJMoa1414264
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132. doi:10.1016/j.ophtha.2012.04.030
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (euretina). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Bellocq D, Bandello F, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema. Eur J Ophthalmol. 2019;29(6):573–584.
   PubMed Web of Science ®Google Scholar
• Gonzalez VH, Campbell J, Holekamp NM, et al. Early and long-term responses to anti–vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol i data. Am J Ophthalmol. 2016;172:72–79. doi:10.1016/j.ajo.2016.09.012
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–136. doi:10.1016/S0140-6736(09)62124-3
   PubMed Web of Science ®Google Scholar
• Alimera Sciences. Iluvien 190 Micrograms Intravitreal Implant in Applicator. Aldershot: Alimera Sciences Limited; 2019.
   Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–35.e2. doi:10.1016/j.ophtha.2010.12.028
   PubMed Web of Science ®Google Scholar
• Loewenstein A, Chakravarthy U. 0.19 mg fluocinolone acetonide intravitreal implant: place in the management of diabetic macular edema. Minerva Oftalmol. 2018;60(2):71–82.
   Google Scholar
• Fusi-Rubiano W, Blow RR, Lane M, Morjaria R, Denniston AK. Iluvien (fluocinolone acetonide 0.19 mg intravitreal implant) in the treatment of diabetic macular edema: a review. Ophthalmol Ther. 2018;7(2):293–305. doi:10.1007/s40123-018-0145-7
   Web of Science ®Google Scholar
• Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aballéa S. Cost-effectiveness of fluocinolone acetonide implant (iluvien®) in uk patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. BMC Health Serv Res. 2019;19(1):22. doi:10.1186/s12913-018-3804-4
   PubMed Web of Science ®Google Scholar
• Quhill F, Beiderbeck A. Cost advantage of fluocinolone acetonide implant (iluvien®) versus ranibizumab in the treatment of chronic diabetic macular oedema. Glob Reg Health Technol Assess. 2017;4(1):grhta.5000268. doi:10.5301/grhta.5000268
   Web of Science ®Google Scholar
• Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4):440–449. doi:10.1016/j.ophtha.2016.11.034
   PubMed Web of Science ®Google Scholar
• Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol i study data. Retina. 2019;39(1):88–97. doi:10.1097/IAE.0000000000002110
   PubMed Web of Science ®Google Scholar
• Alfaqawi F, Lip PL, Elsherbiny S, Chavan R, Mitra A, Mushtaq B. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United kingdom. Eye (Lond). 2017;31(4):650–656. doi:10.1038/eye.2016.301
   PubMed Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J. Real-world experience with 0.2 mug/day fluocinolone acetonide intravitreal implant (iluvien) in the United kingdom. Eye (Lond). 2017;31(12):1707–1715. doi:10.1038/eye.2017.125
   PubMed Web of Science ®Google Scholar
• Fusi-Rubiano W, Mukherjee C, Lane M, et al. Treating diabetic macular oedema (dmo): real world uk clinical outcomes for the 0.19mg fluocinolone acetonide intravitreal implant (iluvien) at 2 years. BMC Ophthalmol. 2018;18(1):62. doi:10.1186/s12886-018-0726-1
   PubMed Web of Science ®Google Scholar
• Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 micrograms intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33(sup2):19–31. doi:10.1080/03007995.2017.1366659
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86. doi:10.1167/iovs.10-5285
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Bopp S, Fechner M, et al. Three-year results from the retro-ideal study: real-world data from diabetic macular edema (DME) patients treated with iluvien® (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol. 2019;1120672119834474.
   Google Scholar
• Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (iluvien): real-world experience in three European countries. Br J Ophthalmol. 2019;103(8):1072–1077. doi:10.1136/bjophthalmol-2018-312284
   PubMed Web of Science ®Google Scholar
• Eaton A, Koh SS, Jimenez J, Riemann CD. The user study: a chart review of patients receiving a 0.2 microg/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8(1):51–62. doi:10.1007/s40123-018-0155-5
   PubMed Web of Science ®Google Scholar